title: Reduction of immunoglobulin levels during imatinib therapy of chronic myeloid leukemia.
authors.forename: Giulia
authors.initials: G
authors.lastname: Cervetti
authors.forename: Giovanni
authors.initials: G
authors.lastname: Carulli
authors.forename: Sara
authors.initials: S
authors.lastname: Galimberti
authors.forename: Antonio
authors.initials: A
authors.lastname: Azzarà
authors.forename: Elisa
authors.initials: E
authors.lastname: Cannizzo
authors.forename: Gabriele
authors.initials: G
authors.lastname: Buda
authors.forename: Enrico
authors.initials: E
authors.lastname: Orciuolo
authors.forename: Mario
authors.initials: M
authors.lastname: Petrini
mesh_terms: D000328:Adult; D000361:Agammaglobulinemia / Q000139:chemically induced* / Q000150:complications; D001549:Benzamides; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000150:complications* / Q000188:drug therapy*; D008297:Male; D010879:Piperazines / Q000009:adverse effects*; D011743:Pyrimidines / Q000009:adverse effects*
chemical_list: D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate